Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.71 | -5.42% | -0.27 |
ALDX closed down 5.42 percent on Friday, August 23, 2019, on 47 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ALDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -5.42% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.83% | |
| Up 3 Days in a Row | Strength | -7.83% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ALDX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 16.7 |
| 52 Week Low | 4.64 |
| Average Volume | 259,646 |
| 200-Day Moving Average | 7.6992 |
| 50-Day Moving Average | 5.7053 |
| 20-Day Moving Average | 5.213 |
| 10-Day Moving Average | 5.057 |
| Average True Range | 0.3044 |
| ADX | 22.77 |
| +DI | 16.7183 |
| -DI | 27.3602 |
| Chandelier Exit (Long, 3 ATRs ) | 5.0868 |
| Chandelier Exit (Short, 3 ATRs ) | 5.5532 |
| Upper Bollinger Band | 5.6644 |
| Lower Bollinger Band | 4.7616 |
| Percent B (%b) | -0.06 |
| BandWidth | 17.318243 |
| MACD Line | -0.2203 |
| MACD Signal Line | -0.2137 |
| MACD Histogram | -0.0066 |
| Fundamentals | Value |
|---|---|
| Market Cap | 29.42 Million |
| Num Shares | 6.25 Million |
| EPS | -1.47 |
| Price-to-Earnings (P/E) Ratio | -3.20 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 4.06 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.43 | ||||
| Resistance 3 (R3) | 5.49 | 5.30 | 5.31 | ||
| Resistance 2 (R2) | 5.30 | 5.12 | 5.28 | 5.27 | |
| Resistance 1 (R1) | 5.01 | 5.01 | 4.92 | 4.95 | 5.23 |
| Pivot Point | 4.82 | 4.82 | 4.78 | 4.80 | 4.82 |
| Support 1 (S1) | 4.53 | 4.64 | 4.44 | 4.47 | 4.19 |
| Support 2 (S2) | 4.34 | 4.53 | 4.32 | 4.15 | |
| Support 3 (S3) | 4.05 | 4.34 | 4.11 | ||
| Support 4 (S4) | 3.99 |
